Clinical Trial

Lurbinectedin or in Combination with Irinotecan Versus Topotecan in Patients with Relapsed SCLC

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
Multicenter, open-label, randomized, controlled phase III clinical trial to evaluate and compare the activity and safety of two experimental arms consisting of Lurbinectedin monotherapy or Lurbinectedin + Irinotecan combined therapy versus Topotecan comparator in Small-cell Lung Cancer (SCLC) patients who failed one prior platinum-containing line.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-07-03.
Status change: Not Yet Recruiting → Recruiting 2024-12-09
Trial Details
NCT Number NCT06496048
Lead Sponsor Luye Pharma Group Ltd.
Conditions Relapsed Small Cell Lung Cancer
Enrollment 180 participants
Start Date 2024-09-14
Primary Completion 2027-12-31 (estimated)
Study Completion 2028-06-30 (estimated)
Updated on ClinicalTrials.gov 2024-12-12